In a recent trial, a new melanoma vaccine, mRNA-4157 (V940), when taken in combination with Keytruda (pembrolizumab), was found to be effective in battling the deadly skin cancer.
People with advanced melanomas who received the vaccine plus Merck’s cancer drug Keytruda were 49 percent less likely to die or have their cancer return after three years than those who were given only Keytruda, vaccine maker Moderna Inc. announced.
“Importantly for this technology, the… study was the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial and the first combination therapy to show a significant benefit over Keytruda alone in adjuvant melanoma,” Moderna Senior Vice President Kyle Holen, M.D., said in a company news release. “We look forward to sharing these data with people impacted by this disease and the broader scientific community.”
The findings are based on an ongoing randomized trial involving 157 patients with high-risk stage 3/4 melanoma who first had surgery to completely remove cancerous growths. Patients received 1 mg of the mRNA vaccine every three weeks for a total of nine doses, along with 200 mg of Keytruda every three weeks for about a year. Their outcomes were compared to those using Keytruda alone for approximately a year.
The companies have already begun Phase III trials of the vaccine-drug combo, and the U.S. Food and Drug Administration has designated the treatment as a breakthrough therapy to speed its development and review.
Related News
NeuExcell’s NXL-004 Secures FDA Orphan Drug Designation for Glioma Treatment
On December 7, 2023, Beijing time, NeuExcell Therapeutics announced that its proprietary AAV gene therapy product, NXL-004, designed for treating malignant glioma, has been awarded Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This...
PackGene Biotech Receives Exclusive C+ Round Investment from SDIC Fund, and Hosts a CGT Industry Salon to Discuss Global Strategies
December 1, 2023, PackGene Biotech, a frontrunner in gene therapy delivery, has successfully closed a landmark C+ funding round, securing over 100 million RMB exclusively from SDIC Fund Management Co., Ltd. This funding, a remarkable accomplishment in the current...
Tauopathy’s Role in Aβ Oligomer Formation: New Insights from Transgenic Primate Models on Alzheimer’s Pathogenesis
Tauopathy, characterized by protein tau and Aβ oligomer accumulation, is a significant aspect of Alzheimer's disease. The causal relationship between these accumulations and neurodegeneration remains unclear despite their links to various cognitive and movement...
Targeted Lysosomal Degradation of Mutant Huntingtin by Engineered Intrabody Peptide SM3
Huntington's disease (HD) is a devastating neurodegenerative condition caused by a mutation in the Huntingtin gene (HTT). This leads to the production of a mutant form of the huntingtin protein (mHTT) with an extended polyglutamine (polyQ) repeat, which has a...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmid CDMO Services
We provide high quality plasmids that are ideal for any phase of the drug development cycle.
READ MORE
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV cGMP Manufacturing
READ MORE
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
AAV Capsid Engineering
Proven technology paving your path to effective therapies for cancer or genetic disorder
READ MORE